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Editorial
Optimising nutrition in cystic fibrosis
1. Introduction
Survival from cystic fibrosis (CF) has substantially
improved over the past four decades. Many factors are
likely to have contributed to improved survival, includ-
ing co-ordinated centre-based care, improved airway
clearance techniques, the advent of broad-spectrum anti-
biotics, earlier neonatal diagnosis by new-born screening
and advances in nutritional management.
Despite these advances, many patients with CF still
do not reach their genetic potential for growth and nutri-
tion, and nutritional and growth deficits are common,
adversely affecting prognosis. In this issue of the Jour-
nal of Cystic Fibrosis, a consensus statement for nutri-
tional management of CF is published w1x. The
document has been prepared by the European Nutrition
Consensus Group on behalf of the European Cystic
Fibrosis Society. These guidelines are timely, and par-
allel new recommendations from a Nutritional Consen-
sus Committee of the US CF Foundation for paediatric
nutrition surveillance and management w2x. Nutritional
status of patients attending CF centres varies consider-
ably, and may reflect variance in nutritional advice and
management provided to patients and their families w3x.
The European guidelines provide a comprehensive
review of the definition, determinants, prevalence and
management of malnutrition and growth failure in CF
and are based on currently available scientific evidence.
Implementation is likely to increase uniformity of nutri-
tional management between European CF clinics, and
improve CF care and outcomes.
2. Why is nutritional status important?
Impaired growth and malnutrition have been associ-
ated with poorer survival in CF, and a wide range of
nutritional deficits with many adverse consequences
have been reported. These facts lend impetus to the
major message in the European guidelines that regular
surveillance for and aggressive management of nutri-
tional deficits at any age of CF life should be a major
part of CF care.
In adults with CF, wasting was predictive of mortality
in CF, but this association is not independent of pul-
monary function w4,5x. A recent study of the large adult
CF service based at the Royal Brompton Hospital in
London has challenged these earlier findings w6x. Sharma
et al. reported that, in an adult cohort, wasting was a
significant predictor of survival, and that this relation-
ship was independent of pulmonary function and indi-
cators of gas exchange w6x. In children with CF, earlier
studies indicated that relative underweight was an inde-
pendent factor adversely affecting survival w7x, and
recent longitudinal analysis of data from the North
American CF Registry has highlighted that growth retar-
dation in children is also a highly significant indicator
of survival w8x. In the latter study, the authors demon-
strated that patients of short stature (stunted) were sig-
nificantly more likely to die before taller patients, and
advocate the utilisation of height-for-age as a method of
screening at risk children. This reinforces the importance
of early detection of slowing of growth leading to active
intervention to attempt to maximise linear growth.
Whilst severity of pulmonary disease and nutritional
status are closely related, it remains unclear whether low
body weight is the cause of or results from declining
pulmonary function. The longitudinal body composition
studies in children with CF by Thomson et al. suggested
that under-nutrition was associated with potentially
reversible deficits in lung growth w9x. Zemel et al. have
recently examined the relationship between growth and
respiratory function in children with CF w10x. This 4-
year longitudinal study in children (5–8 years) with pan-
creatic insufficiency and CF demonstrated that growth
and nutritional status were not stable in pre-pubertal chil-
dren, even in those with mild pulmonary disease. The
authors reported that weight Z-score was correlated with
longitudinal change in FEV , and emphasised that early1
identification of impaired growth may prevent sustained
pulmonary function loss w10x.
Under-nutrition also has an adverse effect on the out-
come from lung transplantation in CF. The risk of death
on a waiting list was extremely high in malnourished
patients (body mass index BMI-18 kgym ), particular-2
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ly for female patients, although it is worth noting that
malnutrition did not adversely influence survival of
patients actually undergoing lung transplantation w11x.
3. Is the prevalence of malnutrition and impaired
growth changing?
Near to normal growth is now widely reported in
younger children with cystic fibrosis; however, body
weight is often sub-optimal in adolescents with CF w12–
14x. Weight and height in young Danish children with
CF is similar to healthy Danish children, but girls ()10
years) and boys ()15 years) were significantly lighter
than control subjects w14x. Some evidence suggests a
reducing overall rate of severe malnutrition in patients
with CF. The proportion of American patients reported
to the Cystic Fibrosis Data Registry who had body
weights below the 5th percentile has decreased from 33
to 24% from 1986 until 1997 w15x.
Whether these apparent advances in nutritional status
in children will result in better preservation in pulmonary
function and or translate into improved nutritional main-
tenance in adults is uncertain. At present, malnutrition
remains a common manifestation in adult with CF w5,6x.
One study reported one in three adults with CF had a
body weight below the 3rd percentile and only 12% had
weights above the 50th percentile w5x.
4. Why is nutritional status improving? How can it
be enhanced further?
Improved growth and nutrition over the past 15 years
may relate to changes in nutritional prescription. Unres-
tricted fat intake and increased utilisation of pancreatic
enzyme replacement (PERT) was widely adopted in the
late 1980s following the study by Corey et al. w13x. This
landmark study reported a 9-year survival advantage in
patients managed at Toronto compared with patients
managed at Boston. The only significant difference
between the two populations was the nature of the nutri-
tional advice.
Lai and colleagues have recently evaluated the nutri-
tional status of patients with CF utilising registry data
(1992–1994) in the USA and Canada w16x. They report
improved nutrition and an apparent reduction in differ-
ences between the USA and Canadian patients. The
mean weight and height percentiles for children were
approximately the 30th in the USA and five percentiles
higher for Canadian patients. In adults with CF, mean
height percentiles were similar in both countries (37th)
and weight indices were greater in Canadian patients
than those from the USA.
Direct comparison between this study and the earlier
one is difficult, as the recent study utilised national data
rather than individual clinic data, and the two studies
utilised different growth standards to assess growth indi-
ces w13,16x. Further study is required to determine the
contributions of clinical, environmental and genetic
influences that may account for the differences between
the two countries.
The nutritional advantages of early diagnosis of CF
has been emphasised by studies of outcomes of neonatal
screening programs, established in some countries, prov-
inces and states over the past 20 years w17–20x. The best
evidence comes from the outcomes of the Wisconsin
Neonatal Screening Study, a randomised trial which
recently reported 13-year follow-up demonstrating sus-
tained nutritional growth advantages in the new-born
diagnosed group w19x. It seems likely that additional
nutritional improvements will, in part, rely on the ready
access to new-born screening programs in regions where
this is not yet available.
5. Assessment of growth and nutritional status
The fact that weight and height measurements should
be performed at all clinic and in-patient assessments is
supported by the published guidelines. Appropriate
equipment for measurement, regular calibration and ade-
quate training of staff are vital for the interpretation of
anthropometric measurements. Z-scores for weight and
height are currently the method of choice to express
anthropometric measurements in children and have an
advantage over weight and height percentiles, as they
reflect divergence of a child’s growth from a reference
median, even at anthropometric extremes w21,22x.
Weight and height measurements are also utilised for
clinical assessment of adults with CF, and nutritional
status is usually expressed as body mass index (BMI)
or percent ideal body weight (% IBW).
However, even when appropriately applied, anthro-
pometric measurements (and their derivatives) lack sen-
sitivity to detect nutritional deficiency in CF. The extent
of malnutrition in children with CF is often underesti-
mated when compared with research measures of body
composition, such as total body potassium w23x. There
is an urgent need to develop and validate sensitive meth-
ods of body composition assessment that are applicable
in routine clinical practice. Currently available bedside
measures, including skin-fold anthropometrics and bio-
electric impedance analysis, have considerable limita-
tions when applied to this population. The role of DEXA
scanning as a reliable measure of body composition
requires further investigation, as it may have dimension-
al limitations.
6. Old treatments, new treatments
Guidelines for nutritional therapy are well-made in the
consensus, and the institution of these should improve
care. It is recognised, however, despite intensive efforts,
including assessment of nutritional intake and absorp-
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tion, optimisation of PERT and prescription of oral high-
energy supplements, that nutritional deficiency can still
occur. A recent meta-analysis has confirmed that enteral
nutritional intervention results in weight gain and
improvement in body composition w24x. Some studies
suggest that, in selected cases, a stabilisation of the
decline in pulmonary function can be achieved by
aggressive nutritional intervention w25x. However, many
questions remain as to the potential effect on pulmonary
function and prognosis. The role of oral high-energy sup-
plements is currently the subject of a multi-centre trial
in the UK.
The role and management of vitamin deficiency is
comprehensively covered within the consensus state-
ment. Deficiency states are frequently observed, with
vitamin A, D, E and K and supplementation recom-
mended. The best marker of deficiency studies is not
well characterised, although serum vitamin levels for
vitamin A, D and E are usually monitored. New tech-
nologies of protein determination may be useful for
monitoring sub-clinical vitamin K deficiency.
New therapies with the potential to improve nutrition
in CF are being studied. Appetite stimulants (megestrol
acetate) and anabolic agents (growth hormone) have
been subject to only limited study in CF, but have dem-
onstrated some promise as adjunctive therapies in the
improvement of nutritional status w26–29x. Multi-centre,
long-term, randomised control trials are needed to eval-
uate more fully their role and potential adverse effects.
Dissatisfaction with weight and body shape is com-
mon in healthy adolescent females. Several studies have
evaluated body image and eating behaviours in young
people with CF w30–32x. Two of these highlight that
females with CF (children and adults) often over-esti-
mate their body weight, despite reduced BMI, and are
generally satisfied with their body size w31,32x. Further
study of the potential societal pressures on eating behav-
iour in women with CF is required, but these preliminary
results should be considered when nutritional advice is
provided to young women with CF.
7. Areas of future research
The European consensus highlights areas where fur-
ther knowledge and evidence are required. Some of the
topics listed are already the subject of clinical and lab-
oratory-based studies. Adequate research funding will be
required to commence addressing many of the nutritional
therapies in the accompanying paper. In the meantime,
the widespread application of these guidelines should go
a long way to improving the health and wellbeing of the
CF population worldwide.
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